Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166188521> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W3166188521 endingPage "7038" @default.
- W3166188521 startingPage "7038" @default.
- W3166188521 abstract "7038 Background: Although adherence to imatinib treatment has been shown to be critical for attaining treatment response among patients with CML, some studies have suggested a 7.3-9.9% nonadherence tolerance margin before loss of treatment effects. We aimed to model probabilistically the margin of tolerance required to ensure treatment response among patients prescribed imatinib and the margin, if any, before treatment response is at risk. Methods: We performed a post hoc analysis of the ADAGIO study conducted in Belgium on 169 evaluable patients ( Blood 2009). Using the pill count ratio as, what in conventional survival analysis would be, the time variable, we modeled the cumulative likelihood of treatment response as a function of increasing pill count adherence. We applied Kaplan-Meier methods to model the likelihood of complete cytogenetic (CCyR), complete hematological (CHR), major molecular (MMR) and optimal (OR) (as defined by the European Leukemia Net) response as a function of 90-day pill count adherence. Kaplan-Meier methods thus estimated the tolerance for nonadherence to imatinib by calculating the 1 minus Kaplan-Meier estimate for treatment response. Results: Analyses (see Table) showed that ̃100% adherence of prescribed dose is associated with probabilities (rounded) of 0.84 for CHR, 0.83 for CCyR, 0.82 for OR, and 0.77 for MMR; compared to, 0.37 (CHR and CCyR), 0.35 (OR), and 0.39 (MMR) at 90% adherence. (of 0.7698 (MMR). Increasing the intake of imatinib from 90% to 100% of the prescribed dose increased the likelihood of the various treatment responses by 1.95 to 2.35-fold. Conclusions: Our findings challenge any previously estimated tolerance for nonadherence. There is virtually no margin for nonadherence if the objective is to optimize the likelihood of treatment response, and only a minimal margin to avoid impaired treatment response. Under such adherence, response rates similar to those in the pivotal IRIS trial can be obtained. Clinicians must assess and promote patient adherence, and patients must be perfectly adherent.[Table: see text]" @default.
- W3166188521 created "2021-06-22" @default.
- W3166188521 creator A5002479254 @default.
- W3166188521 creator A5009185756 @default.
- W3166188521 creator A5076611208 @default.
- W3166188521 creator A5090261710 @default.
- W3166188521 date "2021-05-20" @default.
- W3166188521 modified "2023-09-26" @default.
- W3166188521 title "Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study." @default.
- W3166188521 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.7038" @default.
- W3166188521 hasPublicationYear "2021" @default.
- W3166188521 type Work @default.
- W3166188521 sameAs 3166188521 @default.
- W3166188521 citedByCount "0" @default.
- W3166188521 crossrefType "journal-article" @default.
- W3166188521 hasAuthorship W3166188521A5002479254 @default.
- W3166188521 hasAuthorship W3166188521A5009185756 @default.
- W3166188521 hasAuthorship W3166188521A5076611208 @default.
- W3166188521 hasAuthorship W3166188521A5090261710 @default.
- W3166188521 hasConcept C10515644 @default.
- W3166188521 hasConcept C126322002 @default.
- W3166188521 hasConcept C143998085 @default.
- W3166188521 hasConcept C2777583451 @default.
- W3166188521 hasConcept C2778729363 @default.
- W3166188521 hasConcept C3019892230 @default.
- W3166188521 hasConcept C71924100 @default.
- W3166188521 hasConcept C81603835 @default.
- W3166188521 hasConcept C98274493 @default.
- W3166188521 hasConceptScore W3166188521C10515644 @default.
- W3166188521 hasConceptScore W3166188521C126322002 @default.
- W3166188521 hasConceptScore W3166188521C143998085 @default.
- W3166188521 hasConceptScore W3166188521C2777583451 @default.
- W3166188521 hasConceptScore W3166188521C2778729363 @default.
- W3166188521 hasConceptScore W3166188521C3019892230 @default.
- W3166188521 hasConceptScore W3166188521C71924100 @default.
- W3166188521 hasConceptScore W3166188521C81603835 @default.
- W3166188521 hasConceptScore W3166188521C98274493 @default.
- W3166188521 hasIssue "15_suppl" @default.
- W3166188521 hasLocation W31661885211 @default.
- W3166188521 hasOpenAccess W3166188521 @default.
- W3166188521 hasPrimaryLocation W31661885211 @default.
- W3166188521 hasRelatedWork W1921369781 @default.
- W3166188521 hasRelatedWork W1991789019 @default.
- W3166188521 hasRelatedWork W2071522917 @default.
- W3166188521 hasRelatedWork W2120077570 @default.
- W3166188521 hasRelatedWork W2123135404 @default.
- W3166188521 hasRelatedWork W2149815987 @default.
- W3166188521 hasRelatedWork W2153928148 @default.
- W3166188521 hasRelatedWork W2165746197 @default.
- W3166188521 hasRelatedWork W3080142768 @default.
- W3166188521 hasRelatedWork W2028346583 @default.
- W3166188521 hasVolume "39" @default.
- W3166188521 isParatext "false" @default.
- W3166188521 isRetracted "false" @default.
- W3166188521 magId "3166188521" @default.
- W3166188521 workType "article" @default.